The global Escherichia Coli Strain Market is estimated to be valued at US$ 1.97 Bn or Bn in 2023 and is expected to exhibit a CAGR of 6.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Escherichia coli strains are commonly used in biotechnology for the commercial production of enzymes, antibiotics, hormones, and other chemicals through fermentation. E.coli strains have advantages like high growth rates, ability to grow on inexpensive media, and genetic tractability. They serve as important tools for basic research, production of therapeutics, and industrial fermentation processes.
Market key trends:
One of the key trends in the market is the increasing focus on development of engineered E.coli strains for advanced applications. Various companies are engaged in engineering E.coli to produce high-value compounds and advance synthetic biology capabilities. For instance, researchers at the University of California developed an engineered E.coli strain that can produce psilocybin, a compound found in magic mushrooms. Such engineered novel strains are finding applications in fields like pharmaceuticals and biomanufacturing.
SWOT Analysis
Strengths: E. coli is one of the most widely used and studied model organism. It has well understood genetics and is easy and inexpensive to cultivate and perform experiments.
Weaknesses: Pathogenic strains of E. coli can cause diseases in humans and safety should be a primary concern when handling the bacteria. Variation between strains can also impact research reproducibility.
Opportunities: Development of novel E. coli strains tailored for specific research applications like metabolic engineering, synthetic biology and disease modeling. This expands the applications and potential of E. coli as a cell factory.
Threats: Emergence of antibiotic resistant E. coli strains raises concerns and stringent safety regulations need to be followed for laboratory handling. Alternative model organisms gaining acceptance can threaten E. coli's dominant position.
Key Takeaways
Global Escherichia Coli Strain Market Demand is expected to witness high growth at a CAGR of 6.9% over the forecast period of 2023 to 2030, driven by increasing focus on disease modeling and drug discovery research. The market size for Escherichia Coli strain was valued at US$ 1.97 Bn in 2023.
On the basis of geography, North America dominated the market and accounted for over 35% share in 2023 due to presence of major pharma companies and availability of research funding. However, Asia Pacific is expected to exhibit fastest growth during the forecast period supported by growing biotechnology industry and increasing investments in scientific research from China, India and other countries.
Key players operating in the Escherichia Coli strain market are Thermo Fisher Scientific Inc., Merck KGaA, Novozymes A/S, QIAGEN N.V., Promega Corporation, Agilent Technologies, Inc., New England Biolabs, Inc., Takara Bio Inc., Bio-Rad Laboratories, Inc., GenScript Biotech Corporation. These players are focusing on development of novel E. coli strains tailored to specific customer needs as well as strengthening geographic presence especially in emerging markets of Asia Pacific and Latin America through strategic collaborations and partnerships.
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian